Publication

Selective response of CD5(+) B cell malignancies to activation of the CD72 antigen

Planken, EV., Van de Velde, H., Falkenburg, JHF., Thielemans, K., Willemze, R. & Kluin-Nelemans, JC., Apr-1998, In : Clinical Immunology and Immunopathology. 87, 1, p. 42-49 8 p.

Research output: Contribution to journalArticleAcademicpeer-review

The function of the simultaneous expression of CD5 and its ligand CD72 on B cell malignancies like chronic lymphocytic leukemia and mantle cell lymphoma was assessed. It is unknown if reciprocal interactions between CD72 and CD5 exert an autocrine growth-promoting or -inhibiting effect. CD5(+) (n = 13) and CD5(-) (n = 9) B cell malignancies were cultured with the anti(-) CD72 mAb WL225. For comparison, five other anti-CD72 mAbs were tested, Only CD5(+) B cell malignancies proliferated upon CD72 activation (9 out of 13 cases). A strong suppressive effect of IL-4 on the anti-CD72-induced [H-3]thymidine incorporation, partially caused by downmodulation of the CD72 expression, was seen, Stimulation of the CD5 antigen by L cells transfected with human CD72 (LhCD72) and the anti-CD5 mAb 1C12 exerted no (n = 9) or a minor effect (2 out of 8 cases), respectively. Finally, the results of CD72 stimulation were compared with CD40 stimulation, as this "CD40 system" is an effective method for stimulating B cell malignancies. In 4 of the 7 anti-CD72 responsive cases a costimulatory effect was seen. (C) 1998 Academic Press.

Original languageEnglish
Pages (from-to)42-49
Number of pages8
JournalClinical Immunology and Immunopathology
Volume87
Issue number1
Publication statusPublished - Apr-1998
Externally publishedYes

    Keywords

  • CHRONIC LYMPHOCYTIC-LEUKEMIA, MONOCLONAL ANTI-LYB-2 ANTIBODY, HUMAN LYB-2, LIGAND, CD40, INTERLEUKIN-4, EXPRESSION, MOUSE, IDENTIFICATION, IMMUNOGLOBULIN

ID: 15651621